CASSAVA SCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.34 USD | +2.81% |
|
+13.75% | -0.76% |
| Sales 2024 * | - | Sales 2025 * | 300M 25.01B | Capitalization | 966M 80.55B |
|---|---|---|---|---|---|
| Net income 2024 * | -92M -7.67B | Net income 2025 * | 120M 10.01B | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.22 x |
| P/E ratio 2024 * |
-11.1
x | P/E ratio 2025 * |
13.4
x | Employees | 29 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.82% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +2.81% | ||
| 1 week | +13.75% | ||
| Current month | +10.10% | ||
| 1 month | +10.10% | ||
| 3 months | -7.80% | ||
| 6 months | +12.32% | ||
| Current year | -0.76% |
1 week
20.17
22.46
1 month
19.4426.68
Current year
18.1827.37
1 year
12.3232.10
3 years
12.32146.16
5 years
1.00146.16
10 years
0.76146.16
| Managers | Title | Age | Since |
|---|---|---|---|
Remi Barbier
CEO | Chief Executive Officer | 64 | 01/98/01 |
Eric Schoen
DFI | Director of Finance/CFO | 55 | 01/18/01 |
James Kupiec
CTO | Chief Tech/Sci/R&D Officer | - | 04/21/04 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Remi Barbier
CEO | Chief Executive Officer | 64 | 01/98/01 |
Robert Gussin
BRD | Director/Board Member | 86 | 01/03/01 |
Patrick Scannon
BRD | Director/Board Member | 76 | 07/07/07 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.08% | 237 M€ | +2.89% | - | |
| 0.01% | 9 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 22.34 | +2.81% | 1,080,623 |
| 25/24/25 | 21.73 | +4.77% | 911,679 |
| 24/24/24 | 20.74 | +0.92% | 481,010 |
| 23/24/23 | 20.55 | +0.24% | 499,229 |
| 22/24/22 | 20.5 | +4.38% | 768,603 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotes
Cassava Sciences, Inc. is a biotechnology company focused on Alzheimer's disease. The Company's science is based on stabilizing, but not removing, a critical protein in the brain. The Company is focused on its product discovery and development efforts on disorders of the nervous system. Its lead therapeutic drug candidate, simufilam, is under clinical evaluation for the proposed treatment of Alzheimer's disease dementia in Phase 3 clinical studies. The Company has two biopharmaceutical assets under development. Its lead therapeutic product candidate, called simufilam, is an oral treatment for Alzheimer's disease dementia. Its lead investigational diagnostic product candidate, called SavaDx, is a way to detect the presence of Alzheimer's disease from a small sample of blood. Simufilam targets an altered form of a protein called filamin A in the Alzheimer's brain. It owns rights to its drug and diagnostic assets and related technologies, without royalty obligations to any third party.
Calendar
29/04/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
22.34
USD
Average target price
124
USD
Spread / Average Target
+455.06%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.76% | 966M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- SAVA Stock
